Transplacental transmission of mRNA injections confirmed: does this evidence by Hanna and colleagues support their proposition as a promising prenatal gene therapy?

A recent study by Hanna and collaborators assessed the presence of COVID-19 mRNA productsin the placenta and umbilical cord blood following maternal “vaccination” during human pregnancy.Their analysis of 2 pregnant women revealed that the mRNA of the genetic injections was detected inboth placentas. Spike protein expression was confirmed in the placenta of one of them. Furthermore,the engineered mRNA was detected in the umbilical cord and maternal blood of one mother, wherethose samples were available for analysis. They also found that the integrity of the injected mRNA varied across samples, but overall, a substantial or even overwhelming majority consisted of non-integrous species. The authors also provide several theoretical reasons they believe explain their experiential observations. Based on their results but shifting their aim, the authors indicate the benefits of their results and suggest that related gene therapies, particularly mRNA-based treatments, may have great promise as prenatal therapy. This article analyses the findings and interpretations of the study and identifies gaps and inconsistencies in their explanations. It also provides a short synopsis and update on known problems with mRNA injections and outlines major pitfalls and unknowns underlying thepromised benefits of their intended prenatal gene therapy applications.